ABUS
Arbutus Biopharma CorpCompany with tickers: ABUS
CIK
1447028
CUSIP
03879J100
Shares Outstanding
197,537,710
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Date | Insider | Role | Type | Shares |
|---|---|---|---|---|
| 2026-02-02 | Nguyen Tuan | Chief Financial Officer | Award | 73,500 |
| 2026-02-02 | Nguyen Tuan | Chief Financial Officer | Award | 188,400 |
| 2026-02-02 | Androski Lindsay | Director | Award | 71,700 |
| 2026-02-02 | Androski Lindsay | Director | Award | 28,000 |
| 2025-08-04 | Sawhney Roger | Director | Award | 157,600 |
| 2025-08-04 | Sawhney Roger | Director | Other | 0 |
| 2025-03-31 | Nguyen Tuan | Chief Financial Officer | Award | 750,000 |
| 2025-03-28 | Nguyen Tuan | Chief Financial Officer | Other | 0 |
| 2025-03-18 | Hasija Anuj | Director | Award | 157,600 |
| 2025-03-18 | Beardsley Robert A | Chief Operating Officer | Award | 157,600 |
| 2025-03-18 | Androski Lindsay | Director | Award | 310,422 |
| 2025-02-24 | Beardsley Robert A | Chief Operating Officer | Other | 0 |
| 2025-02-24 | Hasija Anuj | Director | Other | 0 |
| 2025-02-24 | Bishop Joseph E | Director | Other | 0 |
| 2025-02-24 | Androski Lindsay | Director | Other | 0 |
| 2025-02-24 | Gline Matthew | Director, CEO | Other | 38,847,462 |
| 2025-02-14 | Naftzger J. Christopher | General Counsel and CCO | Award | 54,300 |
| 2025-02-14 | Naftzger J. Christopher | General Counsel and CCO | Award | 220,300 |
| 2025-02-14 | McElhaugh Michael J. | Director, Interim President & CEO | Award | 718,800 |
| 2025-02-14 | McElhaugh Michael J. | Director, Interim President & CEO | Award | 177,000 |
| 2025-02-14 | HASTINGS DAVID C | Chief Financial Officer | Award | 90,100 |
| 2025-02-14 | HASTINGS DAVID C | Chief Financial Officer | Award | 365,800 |
| 2025-02-14 | Sims Karen | Chief Medical Officer | Award | 200,300 |
| 2025-02-14 | Sims Karen | Chief Medical Officer | Award | 49,300 |
| 2025-02-04 | McElhaugh Michael J. | Director, Interim President & CEO | Sell | 23,790 |
| 2025-02-04 | Naftzger J. Christopher | General Counsel and CCO | Sell | 11,333 |
| 2025-02-04 | HASTINGS DAVID C | Chief Financial Officer | Sell | 22,183 |
| 2025-02-04 | Sims Karen | Chief Medical Officer | Sell | 19,348 |
| 2024-08-14 | MANCHESTER KEITH S | Director | Convert | 54,915 |
| 2024-08-14 | MANCHESTER KEITH S | Director | Sell | 8,846 |
| 2024-08-14 | MANCHESTER KEITH S | Director | Convert | 54,915 |
| 2024-05-23 | MANCHESTER KEITH S | Director | Award | 67,000 |
| 2024-05-23 | Torti Frank | President and Vant Chair | Award | 67,000 |
| 2024-05-23 | HENRIQUES RICHARD C JR | Director | Award | 67,000 |
| 2024-05-23 | Meyers James R | Director | Award | 67,000 |
| 2024-05-23 | BURGESS DANIEL D | Director | Award | 67,000 |
| 2024-05-23 | Rewolinski Melissa | Director | Award | 67,000 |
| 2024-02-02 | HASTINGS DAVID C | Chief Financial Officer | Sell | 9,593 |
| 2024-02-02 | Sofia Michael J. | Chief Scientific Officer | Sell | 9,982 |
| 2024-02-02 | McElhaugh Michael J. | Director, Interim President & CEO | Sell | 10,164 |
| 2024-02-02 | Sims Karen | Chief Medical Officer | Sell | 4,358 |
| 2024-02-01 | HASTINGS DAVID C | Chief Financial Officer | Award | 112,500 |
| 2024-02-01 | HASTINGS DAVID C | Chief Financial Officer | Award | 450,000 |
| 2024-02-01 | Sofia Michael J. | Chief Scientific Officer | Award | 437,800 |
| 2024-02-01 | Sofia Michael J. | Chief Scientific Officer | Other | 167,162 |
| 2024-02-01 | Sofia Michael J. | Chief Scientific Officer | Award | 109,500 |
| 2024-02-01 | McElhaugh Michael J. | Director, Interim President & CEO | Award | 495,100 |
| 2024-02-01 | McElhaugh Michael J. | Director, Interim President & CEO | Award | 123,800 |
| 2024-02-01 | Naftzger J. Christopher | General Counsel and CCO | Award | 95,100 |
| 2024-02-01 | Naftzger J. Christopher | General Counsel and CCO | Award | 380,500 |
| 2024-02-01 | Sims Karen | Chief Medical Officer | Award | 403,900 |
| 2024-02-01 | Sims Karen | Chief Medical Officer | Award | 101,000 |
| 2023-07-12 | Rewolinski Melissa | Director | Award | 110,000 |
| 2023-07-12 | Rewolinski Melissa | Director | Other | 0 |
| 2023-07-10 | Naftzger J. Christopher | General Counsel and CCO | Award | 500,000 |
| 2023-07-10 | Sims Karen | Chief Medical Officer | Award | 153,640 |
| 2023-07-10 | Sims Karen | Chief Medical Officer | Other | 0 |
| 2023-07-10 | Sims Karen | Chief Medical Officer | Other | 28,900 |
| 2023-07-10 | Sims Karen | Chief Medical Officer | Other | 0 |
| 2023-07-10 | Sims Karen | Chief Medical Officer | Other | 0 |
| 2023-07-10 | Sims Karen | Chief Medical Officer | Other | 0 |
| 2023-07-10 | Sims Karen | Chief Medical Officer | Other | 0 |
| 2023-07-10 | Sims Karen | Chief Medical Officer | Other | 0 |
| 2023-07-10 | Sims Karen | Chief Medical Officer | Other | 0 |
| 2023-07-10 | Naftzger J. Christopher | General Counsel and CCO | Other | 0 |
| 2023-05-24 | HENRIQUES RICHARD C JR | Director | Award | 55,000 |
| 2023-05-24 | BURGESS DANIEL D | Director | Award | 55,000 |
| 2023-05-24 | Torti Frank | President and Vant Chair | Award | 55,000 |
| 2023-05-24 | MANCHESTER KEITH S | Director | Award | 55,000 |
| 2023-05-24 | Meyers James R | Director | Award | 55,000 |
| 2023-02-01 | Sofia Michael J. | Chief Scientific Officer | Other | 167,162 |
| 2023-02-01 | Sofia Michael J. | Chief Scientific Officer | Award | 82,200 |
| 2023-02-01 | Sofia Michael J. | Chief Scientific Officer | Award | 328,700 |
| 2023-02-01 | HASTINGS DAVID C | Chief Financial Officer | Award | 79,000 |
| 2023-02-01 | HASTINGS DAVID C | Chief Financial Officer | Award | 316,000 |
| 2023-02-01 | Collier William H. | Director, President and CEO | Award | 216,500 |
| 2023-02-01 | Collier William H. | Director, President and CEO | Award | 866,000 |
| 2023-02-01 | McElhaugh Michael J. | Director, Interim President & CEO | Award | 83,700 |
| 2023-02-01 | McElhaugh Michael J. | Director, Interim President & CEO | Award | 334,700 |
| 2023-02-01 | Howard Elizabeth | EVP, GC, Compliance | Award | 69,700 |
| 2023-02-01 | Howard Elizabeth | EVP, GC, Compliance | Award | 278,700 |
| 2022-05-25 | Meyers James R | Director | Award | 41,000 |
| 2022-05-25 | HENRIQUES RICHARD C JR | Director | Award | 41,000 |
| 2022-05-25 | BURGESS DANIEL D | Director | Award | 41,000 |
| 2022-05-25 | MANCHESTER KEITH S | Director | Award | 41,000 |
| 2022-05-25 | Torti Frank | President and Vant Chair | Award | 41,000 |
| 2022-05-25 | Tran Tram | Director | Award | 41,000 |
| 2022-01-20 | Collier William H. | Director, President and CEO | Award | 787,550 |
| 2022-01-20 | HASTINGS DAVID C | Chief Financial Officer | Award | 285,000 |
| 2022-01-20 | Sofia Michael J. | Chief Scientific Officer | Award | 285,000 |
| 2022-01-20 | Picchio Gaston | Chief Development Officer | Award | 256,500 |
| 2022-01-20 | McElhaugh Michael J. | Director, Interim President & CEO | Award | 325,850 |
| 2022-01-20 | Howard Elizabeth | EVP, GC, Compliance | Award | 237,500 |
| 2021-12-01 | Sofia Michael J. | Chief Scientific Officer | Other | 167,162 |
| 2021-12-01 | Sofia Michael J. | Chief Scientific Officer | Sell | 200,000 |
| 2021-11-09 | Tran Tram | Director | Other | 0 |
| 2021-11-09 | Tran Tram | Director | Award | 44,000 |
| 2021-06-03 | BURGESS DANIEL D | Director | Award | 22,000 |
| 2021-06-03 | HENRIQUES RICHARD C JR | Director | Award | 22,000 |
| 2021-06-03 | Torti Frank | President and Vant Chair | Award | 22,000 |